| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4319fe3d827bd24add491d4ed90e7692
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8381805eba6d034fc77bd230dd02e6e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8073450a491d200d05b09b9beb6f0ec6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-225
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-564 |
| filingDate |
2019-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17cff54d0cfab980f6d443086c7bf931
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cd6055ad7551e4136131820c5249ee3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01ce218848c6aec92abd4cbd19db182a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3b1306f3577395ece6567c22cd9846b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38d753f003166b16fb1172f9ea226b36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_870a2883cf99e409c8953702faee8b7e |
| publicationDate |
2021-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021386829-A1 |
| titleOfInvention |
Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses |
| abstract |
The present invention provides novel compositions and methods based on the discovery of the mechanisms and gene expression programs associated with homeostatic ILC2s and proinflammatory ILC2s that drive tissue inflammation. Molecular cues were identified that modulate ILC responses to alarmins using single-cell RNA-sequencing (scRNA-seq) profiles of lung-resident ILCs at steady state and after in vivo stimulation. The neuropeptide CGRP and the CGRP receptor were identified as expressed on ILC2s. Treatment with CGRP reduces allergic lung inflammation and reduces the proliferation and expansion of ILC2 cells. The results demonstrate that CGRP signaling strongly modulates ILC2 responses and highlights the importance of neuro-immune crosstalk in allergic inflammatory responses at mucosal surfaces. |
| priorityDate |
2018-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |